Natco Pharma introduces a generic medication for blood cancer treatment in the United States

Summary:
Natco Pharma has launched generic Pomalidomide capsules in the US in partnership with Breckenridge Pharmaceutical, Inc.. The drug, a generic version of Pomalyst marketed by Celgene, is indicated for certain blood and bone marrow cancers, including multiple myeloma and Kaposi sarcoma, and is available in strengths of 1 mg to 4 mg through specialty pharmacies. Company executives said the launch strengthens Natco’s US oncology portfolio and improves patient access through affordable pricing and copay support programs. The product recorded estimated US sales of USD 3.2 billion for the 12 months ended September 2025, and Natco has received 180 days of shared marketing exclusivity from the US Food and Drug Administration. 

Natco Pharma announced on Tuesday that it has introduced generic Pomalidomide capsules in the United States, developed in collaboration with Breckenridge Pharmaceutical, Inc.. The medication is intended for adult patients suffering from blood and bone marrow cancers.

Pomalidomide capsules serve as the generic equivalent of Pomalyst, a brand-name drug marketed by Celgene.

According to a regulatory filing by Natco Pharma, the capsules are offered in strengths of 1 mg, 2 mg, 3 mg, and 4 mg. Distribution will primarily take place through specialty pharmacies and clinics.

Speaking about the launch, Vice Chairman and CEO Rajeev Nannapaneni stated that the addition reinforces the company’s oncology and specialty product portfolio in the US market. He emphasized that the introduction reflects Natco’s continued commitment to improving global access to specialty medications. He also expressed optimism about introducing additional complex and specialty products in the years ahead.

Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, said the company’s rollout of Pomalidomide capsules provides patients with a high-quality and cost-effective generic alternative. He added that copay assistance programs for eligible patients are available to help minimize treatment interruptions and maintain continuity of care. Guy further pointed out that affordability and access remain significant hurdles for individuals relying on specialty treatments.

Natco Pharma stated that Pomalidomide capsules are prescribed for adult patients with multiple myeloma who have undergone at least two previous treatment regimens, including lenalidomide and a proteasome inhibitor, and whose disease progressed during or within 60 days after completing their most recent therapy.

The company also noted that the drug has been approved for patients with AIDS-related Kaposi sarcoma following the failure of highly active antiretroviral therapy, as well as for HIV-negative adults diagnosed with Kaposi sarcoma.

Based on industry sales data, US sales of Pomalidomide capsules in the 1 mg, 2 mg, 3 mg, and 4 mg dosages were estimated at USD 3.2 billion for the 12-month period ending September 2025, the company said.

Natco added that, according to information published by the US Food and Drug Administration (FDA), it is entitled to 180 days of shared marketing exclusivity for the product.